(NASDAQ: CLDX) Celldex Therapeutics's forecast annual revenue growth rate of -2.54% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Celldex Therapeutics's revenue in 2024 is $6,883,000.On average, 2 Wall Street analysts forecast CLDX's revenue for 2024 to be $327,018,972, with the lowest CLDX revenue forecast at $290,683,531, and the highest CLDX revenue forecast at $363,354,414. On average, 2 Wall Street analysts forecast CLDX's revenue for 2025 to be $332,609,040, with the lowest CLDX revenue forecast at $301,863,667, and the highest CLDX revenue forecast at $363,354,414.
In 2026, CLDX is forecast to generate $363,354,414 in revenue, with the lowest revenue forecast at $363,354,414 and the highest revenue forecast at $363,354,414.